Galantamine bioactivity improvement in rat brain using various novel nano-drug delivery systems as therapy for Alzheimer's disease.

Sara Moustafa Kamal


Abstract


Alzheimer's disease, the most common form of dementia, is a neurological disorder. Itis a fatal, progressive and degenerative disease that destroys brain cells.The death of brain cells causes memory loss and cognitive decline. The disease starts mild and gets progressively worse. A comprehensive animal model imitating all the cognitive, behavioural, biochemical and histopathological abnormalities observed in AD patients doesn’t exist. Various researchers report on the potential toxicity of aluminium in experimental animal models and in humans under different clinical conditions. As, Al is a known neurotoxicant that has been reported to alter the BBB under normal physiological conditions and accumulates in the different brain regions and it has also been reported to be involved in the etiology of several neurodegenerative diseases. Current Alzheimer's treatments cannot stop Alzheimer's from progressing, they can temporarily slow the worsening of dementia symptoms and improve quality of life for those with Alzheimer's. Reminyl which contains the active ingredient galantaminehydrobromideis used to treat mild to moderate Alzheimer's disease. It does not cure Alzheimer's disease, but improves memory, awareness, and the ability to perform daily functions. Galantamine increases the level of acetylcholine in the brain by preventing the action of acetylcholinesterase,this slows the breakdown of acetylcholine that is released from remaining undamaged nerve cells in the brain.


Other data

Other Titles تحسين الفاعلية الحيوية لعقارالجالنتامين فى مخ الفئران باستخدام العديد من الأنظمة النانونية المستحدثة كعلاج لمرض الالزهايمر.
Issue Date 2015
URI http://research.asu.edu.eg/handle/12345678/53648


Recommend this item

CORE Recommender

Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.